News from AFFiRiS AG A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

07 Jun, 2017, 11:00 ET AFFiRiS Announces Top Line Results of First-in-Human Clinical Study Using AFFITOPE® PD03A, Confirming Immunogenicity and Safety Profile in Parkinson's Disease Patients

- AFFITOPE® PD03A Safe and Well Tolerated: Primary Endpoint of Phase I Study Met - Dose Dependent Immune Response Against AFFITOPE®...


07 Sep, 2016, 08:30 ET Boost Vaccination Data Encourage Continued Development of AFFiRiS Therapeutic Parkinson's Disease Vaccine Against Alpha-Synuclein

- PD01A was Safe and Well Tolerated: Primary Endpoint of Phase I "Boost" Study Met   - Immune Response was Seen in 86% of Patients,...


05 Feb, 2015, 09:00 ET AFFiRiS AG Announces Management Changes

AFFiRiS announces the appointment of Dr. Arne von Bonin as new member of the Executive Board. Dr. Walter Schmidt and Dr. Frank Mattner resign from...


31 Jul, 2014, 11:10 ET First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development

AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's...


29 Jul, 2014, 09:00 ET Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine

  What:   AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to...


04 Jun, 2014, 05:00 ET Breakthrough in Alzheimer's Disease: AFFiRiS Halted Clinical Progression in Alzheimer Patients Upon Treatment With AD04 in a Phase II Clinical Study

AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to...


27 May, 2014, 11:59 ET Invitation to Press Conference: Alzheimer's Breakthrough - Live Webcast of Worldwide Press Conference

AFFiRiS AG Presents Clinical Phase II Data  Wednesday, 4 June 2014  10.00 am CEST (Central European Summer Time)  08.00 am UTC...


28 Apr, 2014, 09:00 ET Parkinson's Vaccine - Top Experts Unite in European Consortium

An international consortium of top European research teams has received significant EU funding for the development of therapeutic vaccines against...


05 Jun, 2012, 09:00 ET AFFiRiS AG: Parkinson's Vaccine - Worldwide First Clinical Study in Vienna

The worldwide first clinical trial for the development of a Parkinson's vaccine has now been started by AFFiRiS AG. The vaccine called PD01A is...


05 Dec, 2011, 09:00 ET AFFiRiS AG Invests Into Human Capital - Chief Business Officer Recruited

AFFiRiS AG announced today that Ali Alloueche is taking senior responsibility for their expanding business development activities. This new...


08 Nov, 2011, 11:42 ET AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board

Santo VC GmbH has acquired a EUR 20 million stake in Vienna-based AFFiRiS AG effective immediately and has also secured an option for further...


31 May, 2011, 11:00 ET AFFiRiS AG Strengthens its Development Pipeline With the Foundation of a Christian-Doppler-Laboratory

AFFiRiS AG is the industrial Partner of the newly-established Christian-Doppler-Laboratory for Cardiometabolic Immunotherapy. In partnership with...


11 Mar, 2011, 08:59 ET AFFiRiS AG: Alzheimer's Vaccination Shows Promising Results

AFFiRiS' Alzheimer's vaccine candidate AD02 showed indicative evidence for potential efficacy in a phase I clinical trial. This was demonstrated by...


28 Feb, 2011, 10:59 ET AFFiRiS Announces an Extension of its Existing Alzheimer's Disease Vaccine Development Collaboration With GlaxoSmithKline Triggering a Euro 3.5 Million Payment to AFFiRiS

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active...


16 Dec, 2010, 12:21 ET Michael J. Fox Foundation Funds AFFiRiS AG to Develop Parkinson's Vaccine

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS...


23 Apr, 2010, 07:59 ET AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to...


30 Mar, 2010, 09:00 ET Parkinson Vaccination: Good Start to the Spring for AFFiRiS AG

Today AFFiRiS AG announced an important step forward in the development of its vaccine for Parkinson's disease. The vaccine, known as PD01, has...


25 Feb, 2010, 09:00 ET AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million

With immediate effect AFFiRiS AG is starting a development program for vaccination against hypertension. For this project the Austrian Research...


19 Nov, 2009, 04:01 ET AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing

AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate...


20 Oct, 2009, 09:00 ET AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimer's Candidate Vaccines Trigger a EUR 10 Million Milestone Payment

AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02,...


23 Jun, 2009, 04:13 ET AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS

MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity Award competition, hosted by the industry...


27 May, 2009, 09:41 ET AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support

The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU's EUROTRANS-BIO call. The respective...